Biosynthetic pathways of aminoglycosides and their engineering

Je Won Park; Yeon Hee Ban; Sang Jip Nam; Sun Shin Cha; Yeo Joon Yoon

doi:10.1016/j.copbio.2017.03.019

Biosynthetic pathways of aminoglycosides and their engineering

Je Won Park, Yeon Hee Ban, Sang Jip Nam, Sun Shin Cha, Yeo Joon Yoon

Research output: Contribution to journal › Review article › peer-review

18 Citations (Scopus)

Abstract

Despite decades long clinical usage, aminoglycosides still remain a valuable pharmaceutical source for fighting Gram-negative bacterial pathogens, and their newly identified bioactivities are also renewing interest in this old class of antibiotics. As Nature's gift, some aminoglycosides possess natural defensive structural elements that can circumvent drug resistance mechanisms. Thus, a detailed understanding of aminoglycoside biosynthesis will enable us to apply Nature's biosynthetic strategy towards expanding structural diversity in order to produce novel and more robust aminoglycoside analogs. The engineered biosynthesis of novel aminoglycosides is required not only to develop effective therapeutics against the emerging ‘superbugs’ but also to reinvigorate antibiotic lead discovery in readiness for the emerging post-antibiotic era.

Original language	English
Pages (from-to)	33-41
Number of pages	9
Journal	Current Opinion in Biotechnology
Volume	48
DOIs	https://doi.org/10.1016/j.copbio.2017.03.019
Publication status	Published - 2017 Dec 1

Bibliographical note

Funding Information:
We thank Dr Kris Rathwell for critically reading this manuscript. This work was supported by the National Research Foundation of Korea grants (2016R1A2A1A05005078, 2015R1A2A2A01002524 [J.W.P.]) funded by the Ministry of Science, ICT and Future Planning (MISP), and the Intelligent Synthetic Biology Center of the Global Frontier Project funded by MISP (20110031961), Advanced Production Technology Development Program (114048-03-3-CG000) and High Value-added Food Technology Development Program (114019-05-3-HD020), Ministry of Agriculture, Food and Rural Affairs, Republic of Korea. J.W.P. also thanks the Next-Generation BioGreen21 program, Rural Development Administration for its grant (PJ011066).

Publisher Copyright:
© 2017 Elsevier Ltd

ASJC Scopus subject areas

Biotechnology
Bioengineering
Biomedical Engineering

Access to Document

10.1016/j.copbio.2017.03.019

Cite this

@article{b07b7c259dfb4a2fa3a69be26540e2d1,

title = "Biosynthetic pathways of aminoglycosides and their engineering",

abstract = "Despite decades long clinical usage, aminoglycosides still remain a valuable pharmaceutical source for fighting Gram-negative bacterial pathogens, and their newly identified bioactivities are also renewing interest in this old class of antibiotics. As Nature's gift, some aminoglycosides possess natural defensive structural elements that can circumvent drug resistance mechanisms. Thus, a detailed understanding of aminoglycoside biosynthesis will enable us to apply Nature's biosynthetic strategy towards expanding structural diversity in order to produce novel and more robust aminoglycoside analogs. The engineered biosynthesis of novel aminoglycosides is required not only to develop effective therapeutics against the emerging {\textquoteleft}superbugs{\textquoteright} but also to reinvigorate antibiotic lead discovery in readiness for the emerging post-antibiotic era.",

author = "Park, {Je Won} and Ban, {Yeon Hee} and Nam, {Sang Jip} and Cha, {Sun Shin} and Yoon, {Yeo Joon}",

note = "Funding Information: We thank Dr Kris Rathwell for critically reading this manuscript. This work was supported by the National Research Foundation of Korea grants (2016R1A2A1A05005078, 2015R1A2A2A01002524 [J.W.P.]) funded by the Ministry of Science, ICT and Future Planning (MISP), and the Intelligent Synthetic Biology Center of the Global Frontier Project funded by MISP (20110031961), Advanced Production Technology Development Program (114048-03-3-CG000) and High Value-added Food Technology Development Program (114019-05-3-HD020), Ministry of Agriculture, Food and Rural Affairs, Republic of Korea. J.W.P. also thanks the Next-Generation BioGreen21 program, Rural Development Administration for its grant (PJ011066). Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = dec,

day = "1",

doi = "10.1016/j.copbio.2017.03.019",

language = "English",

volume = "48",

pages = "33--41",

journal = "Current Opinion in Biotechnology",

issn = "0958-1669",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Biosynthetic pathways of aminoglycosides and their engineering

AU - Park, Je Won

AU - Ban, Yeon Hee

AU - Nam, Sang Jip

AU - Cha, Sun Shin

AU - Yoon, Yeo Joon

N1 - Funding Information: We thank Dr Kris Rathwell for critically reading this manuscript. This work was supported by the National Research Foundation of Korea grants (2016R1A2A1A05005078, 2015R1A2A2A01002524 [J.W.P.]) funded by the Ministry of Science, ICT and Future Planning (MISP), and the Intelligent Synthetic Biology Center of the Global Frontier Project funded by MISP (20110031961), Advanced Production Technology Development Program (114048-03-3-CG000) and High Value-added Food Technology Development Program (114019-05-3-HD020), Ministry of Agriculture, Food and Rural Affairs, Republic of Korea. J.W.P. also thanks the Next-Generation BioGreen21 program, Rural Development Administration for its grant (PJ011066). Publisher Copyright: © 2017 Elsevier Ltd

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Despite decades long clinical usage, aminoglycosides still remain a valuable pharmaceutical source for fighting Gram-negative bacterial pathogens, and their newly identified bioactivities are also renewing interest in this old class of antibiotics. As Nature's gift, some aminoglycosides possess natural defensive structural elements that can circumvent drug resistance mechanisms. Thus, a detailed understanding of aminoglycoside biosynthesis will enable us to apply Nature's biosynthetic strategy towards expanding structural diversity in order to produce novel and more robust aminoglycoside analogs. The engineered biosynthesis of novel aminoglycosides is required not only to develop effective therapeutics against the emerging ‘superbugs’ but also to reinvigorate antibiotic lead discovery in readiness for the emerging post-antibiotic era.

AB - Despite decades long clinical usage, aminoglycosides still remain a valuable pharmaceutical source for fighting Gram-negative bacterial pathogens, and their newly identified bioactivities are also renewing interest in this old class of antibiotics. As Nature's gift, some aminoglycosides possess natural defensive structural elements that can circumvent drug resistance mechanisms. Thus, a detailed understanding of aminoglycoside biosynthesis will enable us to apply Nature's biosynthetic strategy towards expanding structural diversity in order to produce novel and more robust aminoglycoside analogs. The engineered biosynthesis of novel aminoglycosides is required not only to develop effective therapeutics against the emerging ‘superbugs’ but also to reinvigorate antibiotic lead discovery in readiness for the emerging post-antibiotic era.

UR - http://www.scopus.com/inward/record.url?scp=85016425152&partnerID=8YFLogxK

U2 - 10.1016/j.copbio.2017.03.019

DO - 10.1016/j.copbio.2017.03.019

M3 - Review article

C2 - 28365471

AN - SCOPUS:85016425152

SN - 0958-1669

VL - 48

SP - 33

EP - 41

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

ER -

Biosynthetic pathways of aminoglycosides and their engineering

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this